Hemangiomas are common in infants, and often appear within the first few weeks of life. Although many infant hemangiomas are unsightly but regress after a few months, others can be large and disfiguring. Until recently, there have been no ideal treatment options, but there has been recent success using propranolol to treat infant hemangiomas. Host Dr. Michael Greenberg explores this exciting new treatment with Dr. Buddy Cohen, professor of dermatology and pediatrics at Johns Hopkins University School of Medicine.
Beta-Blockers: New Treatment for Infant Hemangiomas
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Hemangiomas are common in infants, and often appear within the first few weeks of life. Although many infant hemangiomas are unsightly but regress after a few months, others can be large and disfiguring. Until recently, there have been no ideal treatment options, but there has been recent success using propranolol to treat infant hemangiomas. Host Dr. Michael Greenberg explores this exciting new treatment with Dr. Buddy Cohen, professor of dermatology and pediatrics at Johns Hopkins University School of Medicine.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
HF Management for Patients with Comorbid Conditions
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?